Drug Patent Expirations in October 2010

*Drugs may be covered by multiple patents

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
ORGARAN	Organon Usa Inc	danaparoid sodium	5,164,377	Oct 3, 2010
MIRAPEX ER	Boehringer Ingelheim	pramipexole dihydrochloride	4,886,812	Oct 8, 2010
MIRAPEX	Boehringer Ingelheim	pramipexole dihydrochloride	4,886,812	Oct 8, 2010
CLIMARA PRO	Bayer Hlthcare	estradiol; levonorgestrel	5,770,219	Oct 12, 2010
CLIMARA PRO	Bayer Hlthcare	estradiol; levonorgestrel	5,252,334	Oct 12, 2010
MENTAX	Mylan	butenafine hydrochloride	5,021,458	Oct 18, 2010
NUVIGIL	Cephalon	armodafinil	4,927,855*PED	Oct 22, 2010
CETROTIDE	Emd Serono	cetrorelix	5,198,533	Oct 24, 2010
TRITEC	Glaxosmithkline	ranitidine bismuth citrate	5,256,684	Oct 26, 2010
INVEGA SUSTENNA	Johnson And Johnson	paliperidone palmitate	5,254,556	Oct 27, 2010
COMTAN	Orion	entacapone	5,135,950	Oct 31, 2010
STALEVO 125	Orion	carbidopa; entacapone; levodopa	5,135,950	Oct 31, 2010
STALEVO 200	Orion	carbidopa; entacapone; levodopa	5,135,950	Oct 31, 2010
STALEVO 75	Orion	carbidopa; entacapone; levodopa	5,135,950	Oct 31, 2010
STALEVO 100	Orion	carbidopa; entacapone; levodopa	5,135,950	Oct 31, 2010
STALEVO 150	Orion	carbidopa; entacapone; levodopa	5,135,950	Oct 31, 2010
STALEVO 50	Orion	carbidopa; entacapone; levodopa	5,135,950	Oct 31, 2010

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com

0 Comments/

0 Likes

/2 Tweets/in General Biotechnology

October 4, 2010

04 Oct 2010

Developing a biotechnology cluster in Japan

The panel on applying Design Thinking to biotechnology was well received, and I look forward to writing up my observations.

I’m now in Japan for a workshop on developing a biotechnology cluster. The U.S. biotechnology industry – the largest in the world – was basically developed with strong support from Japanese pharmaceutical and brewing companies. I look forward to developing new insights on what Japan can do to bolster its biotechnology industry.

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology, Talks and Publications

September 28, 2010

28 Sep 2010

Biotechnology and a Better World by Design

I will be moderating a panel on the roles of biotechnology in development at the upcoming A Better World by Design conference at Brown University. The theme of the panel will be the promise and challenges of implementing biotechnology advances for public benefit, with a focus on topics such as disease prevention, agricultural improvements, and political hurdles.

The panel will be on October 1st at Brown University. For more details, see the A Better World by Design website.

1 Comment/

0 Likes

/1 Tweets/in General Biotechnology, Talks and Publications

September 11, 2010

11 Sep 2010

Medicine for Tomorrow: An Article on Pharmaceutical Research and Development by Nobel Prize-Winning Economist Joseph Stiglitz

As stringent new budgets have led to pharmaceutical companies cutting back, a certain concern and scepticism has risen over the high prices charged by drug companies, their continued problems with productivity, and falling success rates of new drugs. A significant drop in investment in drugmaking companies, and president Obama’s recent reforms of the healthcare system in the USA, feel like a precursor to change in a sector that traditionally relies on older products and philosophies, rather than innovating.

In a recent issue of the Journal of Generic Medicines, world-renowned economist Joseph Stiglitz and economics professor and Roosevelt Institute fellow Arjun Jayadev examine pharmaceutical R&D from a fresh economic perspective.

Stiglitz and Jayadev put forward the argument that current models of pharmaceutical drug discovery have major inefficiencies, and suggest four different policies to address them. They propose meaningful, realistic plans and pricing models to minimise costs to the public sector, maximise positive social impact and remedy the irrationalities in the current system.

Progressive and unafraid of controversy, the article’s arguments for how to improve pharmaceutical R&D are a must-read for anyone in the industry, as well as academics, policy-makers, stakeholders and members of government.

The article is available on the Journal of Generic Medicines website.

0 Comments/

1 Likes

/4 Tweets/in Biotechnology Industry News

September 10, 2010

10 Sep 2010

New reports from DrugPatentWatch

New Reports Based on Data-Mining the DrugPatentWatch database

Please contact us with any special data requirements beyond the existing report catalog

Orphan Drug Report

The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity

The Report includes:

The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug
Details on each NDA and product number, including Dosage, Strength, Approval Date, Therapeutic Equivalence (TE) code, Reference Listed Drug (RLD) indicator
All FDA-listed patents covering each Orphan Drug

Report highlights:

More than 100 pages
More than 80 drugs profiled

More information is available at http://www.thinkpharm.com/orphan-drug-report.html

Drug Patent Challenge Report

The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drugs patents.

Using data on drugs approved from 2000 to 2009, this report provides complete lists of:

A list of the companies with the most successful patent challenges
A list of all the drugs for which each firm successfully challenged a patent
A list of all the companies that have received FDA approval for each listed drug

Report Highlights: